Department of Microbiology and Immunology, Department of Medicine (Oncology), Albert Einstein
College of Medicine, Bronx, NY 10461, USA
CTLA-4 and the PD-1/PD-L1 pathway are current focuses for cancer immunotherapy. This presentation will discuss other new immune checkpoints for future human cancer. Dr. Zang laboratory has focused on discovery and functional dissection of new pathways for T cell costimulation and co-inhibition, with the objective of applying new knowledge to the goals of improved vaccines and new therapeutic strategies for human cancers, autoimmune disorders, infection, and transplant rejection. More information can be found on the lab homepage: http://www.einstein.yu.edu/zang/.